"Designing Growth Strategies is in our DNA"

U.S. Ophthalmic Disease Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, and Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration, Diabetic Retinopathy}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI108840

 

  1. Introduction
    1. Market Scope
    2. Market Segmentation
    3. Market Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Ophthalmic Diseases, 2022
    2. Pipeline Analysis, By Key Players
    3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
    4. Regulatory Scenario in U.S.
    5. Impact of COVID-19 on the Market
  5. U.S. Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Regeneron Pharmaceuticals Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. AbbVie Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Genentech USA, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Viatris Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Novartis AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Bayer AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. F. Hoffmann-La Roche Ltda
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Table 01: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Drug Class, 2019–2030

Table 02: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Anti-glaucoma, 2019–2030

Table 03: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Dosage Form, 2019–2030

Table 04: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2030

Table 05: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019–2030

Table 06: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019–2030

Table 07: U.S. Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2030

Figure 01: U.S. Ophthalmic Disease Therapeutics Market Revenue Breakdown (USD billion, %) by Type, 2022 & 2030

Figure 02: U.S. Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022 & 2030

Figure 03: U.S. Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022 & 2030

Figure 04: U.S. Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022 & 2030

Figure 05: U.S. Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 06: U.S. Ophthalmic Disease Therapeutics Market Share (%), By Company, 2022

U.S. Ophthalmic Disease Therapeutics Market Size, Share and Global Industry Trend Forecast till 2030
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Consulting Services
    How will you benefit from our consulting services ?